| Citation: |
NIMA Zhuoma, XIAO Yu, LUO Hanhuan, DUO Bula, WANG Han, DA Zhen, SILANG Jiangcun, GUO Pingping, LIAO Ruiqian. Expression and Significance of GATA-3, H3K27me3 in Tibetan Patients with Bladder Urothelial Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 953-959. DOI: 10.12290/xhyxzz.2023-0595
|
To investigate the expression and clinical significance of GATA-3 and H3K27me3 in Tibetan patients with bladder urothelial carcinoma (BUC).
BUC and normal bladder tissues were collected retrospectively from January 2016 to December 2021 in the People's Hospital of Tibet Autonomous Region. The expression of GATA-3 and H3K27me3 in both tissues was detected by immunohistochemical method, and the clinical and pathological characteristics were statistically analyzed.
A total of 70 patients with BUC were selected, including 51 males and 19 females, with an average age of (60.5±12.0) years. At the same time, 20 normal bladder tissue samples were collected during the same period. All cases were Tibetan patients. Immunohistochemistry results showed that the high expression rate of GATA-3 in BUC and normal bladder tissue was 70.0%(49/70) and 100%(20/20), respectively. High expression of GATA-3 was associated with male, low pathological grade, and non-invasive tissue(all P < 0.05). The high expression rate of H3K27me3 in BUC and normal bladder tissue was 45.7%(32/70) and 20.0%(4/20), respectively. High expression of H3K27me3 was only associated with male (P=0.011).
The expression of GATA-3 was down regulated in Tibetan BUC patients, and significantly down regulated with the increase of tumor grade, suggesting that GATA-3 may be involved in the occurrence and development of BUC and related to its malignancy, providing reference for clinical diagnosis and treatment as well as judging disease prognosis. The expression of H3K27me3 in Tibetan BUC patients was higher than that in normal bladder tissue, suggesting that H3K27me3 may be a new immune marker for diagnosis of BUC.
| [1] |
国家癌症中心, 国家肿瘤质控中心膀胱癌质控专家委员会. 中国膀胱癌规范诊疗质量控制指标(2022版)[J]. 中华肿瘤杂志, 2022, 44(10): 1003-1010. DOI: 10.3760/cma.j.cn112152-20220803-00531
National Cancer Center, Bladder Cancer Expert Committee of National Cancer Quality Control Center. Quality control index for standardized diagnosis and treatment of bladder cancer in China (2022 edition)[J]. Chin J Oncol, 2022, 44(10): 1003-1010. DOI: 10.3760/cma.j.cn112152-20220803-00531
|
| [2] |
Khazaeli Najafabadi M, Mirzaeian E, Memar Montazerin S, et al. Role of GATA3 in tumor diagnosis: a review[J]. Pathol Res Pract, 2021, 226: 153611. DOI: 10.1016/j.prp.2021.153611
|
| [3] |
徐静纯, 王聪. H3K27me3在肿瘤中的研究进展[J]. 南京医科大学学报(自然科学版), 2022, 42(6): 897-902. https://www.cnki.com.cn/Article/CJFDTOTAL-NJYK202206022.htm
Xu J C, Wang C. Research progress of H3K27me3 in tumors[J]. J Nanjing Med Univ (Nat Sci), 2022, 42(6): 897-902. https://www.cnki.com.cn/Article/CJFDTOTAL-NJYK202206022.htm
|
| [4] |
李幸达, 孙卫兵, 蒋葵. GATA3在上尿路上皮癌中的表达及临床意义[J]. 临床泌尿外科杂志, 2020, 35(2): 112-116. https://www.cnki.com.cn/Article/CJFDTOTAL-LCMW202002006.htm
Li X D, Sun W B, Jiang K. Expression and clinical significance of GATA3 in epithelial carcinoma of upper urinary tract[J]. J Clin Urol, 2020, 35(2): 112-116. https://www.cnki.com.cn/Article/CJFDTOTAL-LCMW202002006.htm
|
| [5] |
Samal S, Patnaik A, Sahu F, et al. Altered expression of epigenetic modifiers EZH2, H3K27me3, and DNA methyltransferases in meningiomas-prognostic biomarkers for routine practice[J]. Folia Neuropathol, 2020, 58(2): 133-142. DOI: 10.5114/fn.2020.96970
|
| [6] |
谢轶群, 裔海鹰, 施俊义, 等. GATA3在乳腺癌中的表达及其与预后的关系[J]. 中国癌症杂志, 2010, 20(12): 911-914. DOI: 10.3969/j.issn.1007-3639.2010.12.007
Xie Y Q, Yi H Y, Shi J Y, et al. Expression of GATA3 in breast cancer tissues and the relationship between GATA3 and the prognosis of breast cancer[J]. China Oncol, 2010, 20(12): 911-914. DOI: 10.3969/j.issn.1007-3639.2010.12.007
|
| [7] |
朱匡政. T-bet、GATA-3在膀胱尿路上皮癌组织中的检测及临床意义[D]. 兰州: 西北民族大学, 2020.
Zhu K Z. Detection and clinical significance of T-bet and GATA-3 in bladder urothelial carcinoma[D]. Lanzhou: Northwest Minzu University, 2020.
|
| [8] |
冯春. AR、GATA3在膀胱尿路上皮癌的表达及与临床病理的关系[D]. 西宁: 青海大学, 2019.
Feng C. Expression of AR, GATA3 in bladder urothelial carcinoma and its relationship with clinical pathology[D]. Xining: Qinghai University, 2019.
|
| [9] |
袁丽倩, 陈曲, 李红英. 膀胱尿路上皮癌中GATA3的表达及与Ki-67的相关性分析[J]. 诊断病理学杂志, 2021, 28(8): 635-638. DOI: 10.3969/j.issn.1007-8096.2021.08.007
Yuan L Q, Chen Q, Li H Y. Expression of GATA3 in bladder urothelial carcinoma and its correlation with Ki-67[J]. Chin J Diagn Pathol, 2021, 28(8): 635-638. DOI: 10.3969/j.issn.1007-8096.2021.08.007
|
| [10] |
开蕾, 张二春, 彭钧. 膀胱尿路上皮癌组织CD44 V6、GATA-3的表达变化及与肿瘤病理分级的关系[J]. 山东医药, 2016, 56(9): 75-76. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYY201609031.htm
Kai L, Zhang E C, Peng J. The expression changes of CD44 V6 and GATA-3 in bladder urothelial carcinoma tissue and their relationship with tumor pathological grading[J]. Shandong Med J, 2016, 56(9): 75-76. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYY201609031.htm
|
| [11] |
钟凯华. GATA-3蛋白在调控膀胱尿路上皮癌生物学行为中的作用及与复发的关系研究[J]. 解剖学研究, 2017, 39(1): 9-12. https://www.cnki.com.cn/Article/CJFDTOTAL-GDJP201701003.htm
Zhong K H. The regulation effect of GATA-3 proteins in bladder urothelial carcinoma biology behavior and relation-ship with the recurrence[J]. Anat Res, 2017, 39(1): 9-12. https://www.cnki.com.cn/Article/CJFDTOTAL-GDJP201701003.htm
|
| [12] |
Inoue S, Mizushima T, Fujita K, et al. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator[J]. Hum Pathol, 2017, 64: 83-90. DOI: 10.1016/j.humpath.2017.04.003
|
| [13] |
Huber J P, Gonzales-Van Horn S R, Roybal K T, et al. IFN-α suppresses GATA3 transcription from a distal exon and promotes H3K27 trimethylation of the CNS-1 enhancer in human Th2 cells[J]. J Immunol, 2014, 192(12): 5687-5694. DOI: 10.4049/jimmunol.1301908
|
| [14] |
Levy S, Somasundaram L, Raj I X, et al. dCas9 fusion to computer-designed PRC2 inhibitor reveals functional TATA box in distal promoter region[J]. Cell Rep, 2022, 38(9): 110457. DOI: 10.1016/j.celrep.2022.110457
|
| [15] |
Wei Y K, Xia W Y, Zhang Z H, et al. Loss of trimethyla-tion at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers[J]. Mol Carcinog, 2008, 47(9): 701-706. DOI: 10.1002/mc.20413
|
| [16] |
He W P, Li Q, Zhou J, et al. Decreased expression of H3K27me3 in human ovarian carcinomas correlates with more aggressive tumor behavior and poor patient survival[J]. Neoplasma, 2015, 62(6): 932-937. DOI: 10.4149/neo_2015_113
|
| [17] |
Cai M Y, Tong Z T, Zhu W, et al. H3K27me3 protein is a promising predictive biomarker of patients' survival and chemoradioresistance in human nasopharyngeal carcinoma[J]. Mol Med, 2011, 17(11/12): 1137-1145.
|
| [18] |
Lin S F, Zhou M H, Li Y P, et al. H3K27 trimethylation and H3K9 dimethylation as poor prognostic markers for patients with esophageal squamous cell carcinoma[J]. Int J Clin Exp Pathol, 2019, 12(7): 2657-2664.
|
| [19] |
Di Croce L, Helin K. Transcriptional regulation by Polycomb group proteins[J]. Nat Struct Mol Biol, 2013, 20(10): 1147-1155. DOI: 10.1038/nsmb.2669
|
| [20] |
罗含欢, 霍真, 王倩, 等. 西藏地区脑膜瘤临床病理观察[J]. 中国医学科学院学报, 2022, 44(4): 621-627. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYKX202204011.htm
Luo H H, Huo Z, Wang Q, et al. Clinicopathological features of meningiomas in Tibet[J]. Acta Acad Med Sin, 2022, 44(4): 621-627. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYKX202204011.htm
|
| [21] |
罗含欢, 师杰, 边巴扎西, 等. 西藏地区藏族人群胃癌组织中H3K27me3表达水平及其临床意义[J]. 协和医学杂志, 2022, 13(6): 1088-1093. DOI: 10.12290/xhyxzz.2021-0727
Luo H H, Shi J, Bianbazaxi, et al. Expression of H3K27me3 in Tibetan patients with gastric cancer and its significance[J]. Med J PUMCH, 2022, 13(6): 1088-1093. DOI: 10.12290/xhyxzz.2021-0727
|
| [22] |
Liu J Y, Li Y H, Liao Y J, et al. High expression of H3K27me3 is an Independent predictor of worse outcome in patients with urothelial carcinoma of bladder treated with radical cystectomy[J]. Biomed Res Int, 2013, 2013: 390482.
|
| [1] | WANG Caihong, LIU Rongxin, TANG Feng, WEI Xiaotao, XU Ziqing, HOU Huaijing, ZHANG Jie, ZHAO Yongqiang, XUE Jianjun. Research Progress on the Role of NLRP3 Inflammasome and Microglia in Cognitive Impairment[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1282-1288. DOI: 10.12290/xhyxzz.2023-0217 |
| [2] | LUO Hanhuan, SHI Jie, BIANBA Zhaxi, YANG Xu, NIMA Zhuoma, WANG Qian, LI Mei, WANG Han, LIAO Ruiqian, CIREN Quzhen. Expression of H3K27me3 in Tibetan Patients with Gastric Cancer and Its Significance[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 1088-1093. DOI: 10.12290/xhyxzz.2021-0727 |
| [3] | MA Dongjiang, DENG Chengwu, WEI Cheng, LYU Bingzhe, WANG Chen. Characteristics of Transcription Factor POU3F2 and Its Research Progress in Tumorigenesis and Development[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 858-863. DOI: 10.12290/xhyxzz.2022-0008 |
| [4] | ZHANG Xi, HUANG Bing, WANG Guipeng. Progress of NLRP3 Inflammasome and Myocardial Ischemia Reperfusion Injury[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 296-301. DOI: 10.12290/xhyxzz.2021-0619 |
| [5] | Jin Wen, Hanzhong Li, Zhigang Ji. Effectiveness Assessment of Partial Nephrectomy with Flexible Three-dimensional Laparoscopy[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(1): 43-45. DOI: 10.3969/j.issn.1674-9081.2017.01.010 |
| [7] | Nai-xin LIANG, Ya-xin LIU, Lei LIU, Shan-qing LI. Co-mutation of PIK3CA and Other Oncogenes in Patients with Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(3): 186-190. DOI: 10.3969/j.issn.1674-9081.2015.03.005 |
| [8] | Ming-yang LIU, Jie CHEN, Jian GUAN. Local Injections of Cholesterol-conjugated let-7a Mimics Inhibit Tumor Growth and Metastasis of Hepatocellular Carcinoma in a Subcutaneous Xenograft Nude Mouse Model by Targeting K-Ras, H-Ras, and N-Ras[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(2): 133-139. DOI: 10.3969/j.issn.1674-9081.2015.02.012 |
| [9] | Wen-ze WANG, Guo-tao MA, Yu XIAO, Zhi-yong LIANG, Wei-zhen LOU, Ji LI, Da-chun ZHAO, Huan-wen WU, Tong-hua LIU. Different Expressions of Bcl-2 and Vascular Endothelial Growth Factor Receptor-3 in Intravenous Leiomyomatosis and Classical Leiomyoma[J]. Medical Journal of Peking Union Medical College Hospital, 2014, 5(3): 297-301. DOI: 10.3969/j.issn.1674-9081.2014.03.010 |
| 1. |
宋永波，赵璐，张艳苓，任武. 重组人血管内皮抑制素注射液联合GP化疗方案治疗晚期NSCLC的可行性. 临床合理用药. 2024(12): 13-16 .
| |
| 2. |
刘家骏，刘国康，朱玉虎. 免疫相关性重症肺炎1例. 北京大学学报(医学版). 2024(05): 932-937 .
| |
| 3. |
李蓉. 肿瘤微环境与免疫检查点抑制剂在晚期非小细胞肺癌治疗中的协同效应. 结核与肺部疾病杂志. 2024(S1): 27-29 .
| |
| 4. |
王冰冰，高宏，李夏平. 中晚期恶性肿瘤患者中药联合免疫检查点抑制剂治疗的疗效相关性探析. 中医临床研究. 2023(14): 50-56 .
| |
| 5. |
王峰，李梅，张艳，沈洪. 艾迪注射液联合化疗治疗晚期非小细胞肺癌的疗效及安全性分析. 中国现代药物应用. 2023(23): 25-28 .
|
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Submit
Review
Office
Email Alert
RSS
DownLoad: